X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to evaluate safety and efficacy of X-396(Ensartinib) capsule
in patients with ALK-positive non-small cell lung cancer previously treated with
crizotinib.While exploring the relationship between biomarkers and drug efficacy and safety.